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What is the difference between IgA nephropathy and Henoch- modern definition of the disease. The latter has been
Scho¨nlein purpura nephritis? Henoch-Scho¨nlein purpura ne- recently formulated by the International Consensus Con-
phritis (HSPN) and IgA nephropathy (IgAN) are considered ference on Nomenclature of Systemic Vasculitides as “ato be related diseases since both can be encountered consecu-
vasculitis with IgA-dominant immune deposits affectingtively in the same patient, they have been described in twins,
small vessels and typically involving skin, gut, and glo-and bear identical pathological and biological abnormalities.
Apart from the presence of extrarenal clinical signs found meruli and associated with arthralgias or arthritis” [5].
only in HSPN, other differences are noticed between the two In 1968, Berger and Hinglais reported for the first time
diseases. The peak age ranges between 15 and 30 years for a
a form of glomerulonephritis characterized by mesangialdiagnosis of IgAN, whereas HSPN is mainly seen in childhood.
accumulation of IgA associated with less intense depositsNephritic and/or nephrotic syndromes are more often seen at
presentation in HSPN. In contrast to IgAN, HSPN has been of IgG and/or C3 [6]. Light microscopy revealed mainly
described in association with hypersensitivity. Endocapillary focal and segmental mesangial proliferation and matrix
and extracapillary inflammations as well as fibrin deposits in the expansion, whereas electron-dense deposits were dem-glomerulus are more frequent in HSPN. No major biological
onstrated by electron microscopy between the glomeru-differences have been found between the two illnesses, except
lar basement membrane and mesangial cells (MCs). Thefor a larger size of circulating IgA-containing complexes (IgA-
CC) and a greater incidence of increased plasma IgE levels in finding of glomerular IgA deposits led later on to the
HSPN. As tissue infiltration by leukocytes is a major feature denomination of IgA nephropathy (IgAN). At the same
of HSPN vasculitis, a possible role of a more potent activation
time, Urizar et al showed similar pathological findingsof the latter cells by IgA-CC and/or circulating chemokines in
in renal biopsies of patients with Henoch-Scho¨nlein pur-HSPN should be considered. Further studies are required to
elucidate this possible mechanism as well as the role of hyper- pura nephritis (HSPN) [7].
sensitivity in HSPN. Henoch-Scho¨nlein purpura nephritis and IgAN cur-
rently are considered to be related diseases since both can
be encountered consecutively in the same patient [8], have
Heberden was probably the first to report a case of been described in identical twins [9], and bear identical
Henoch-Scho¨nlein purpura [1]. He described a five-year- pathological and biological abnormalities [10, 11]. The
old boy presenting with generalized edema, macroscopic present review points out the similarities and differences
hematuria associated with a purpuric rash, colicky pain, between the two diseases in order to propose pathoge-
bloody stools, and arthralgia. The association between netic mechanisms that may explain the occurrence of
an erythematous or purpuric rash and joint pain was systemic vasculitis in HSPN only (Tables 1 and 2).
reported again by Scho¨nlein [2]. Scho¨nlein’s former pu-
pil, Henoch, described four children with a combination
of rash, colic, bloody diarrhea, and joint pain [3] and, in PREVALENCE, DISTRIBUTION, AGE, AND SEX
a later report added hemorrhagic nephritis to the list of IgA nephropathy represents 1.6% of all new cases of
components of the syndrome [4], thus completing the end-stage renal failure (ESRF) recorded in the Euro-
pean Dialysis and Transplantation Association registry
for the year 1988 [12]. In a large series of children withKey words: vasculitis, crescents, immunological abnormalities, allergy,
leukocytes, circulating chemokines, hypersensitivity. ESRF recorded in France [13], 1.3% had IgAN. The
overall prevalence of IgAN is not known. However, the
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Table 2. Differences between IgAN and HSPNTable 1. Similarities of IgAN and HSPN
IgAN HSPNClinical features
More frequent in male
Clinical featuresGross hematuria simultaneous to a respiratory infection
Extra-renal symptoms 2 1Frequent evolution to chronic renal insufficiency
Age at onset .15 y ,15 yRelapse after transplantation
Nephritic/nephrotic syndrome 1/2 111Histology
Risk of chronic renal failure (CRF) 1 11Predominant mesangial IgA1 deposits
Hypersensitivity 2 1Electron dense deposits in the mesangium
Secondary forms 11 1/2Mesangial proliferation
HistologyCutaneous IgA deposits
Endocapillary proliferation 1/2 11IgA immunological abnormalities
Epithelial crescents 1/2 11Abnormal IgA1 glycosylation pattern
Perivascular glomerular IgA 1/2 11Increased IgA plasma levels
Subepithelial/subendothelial dense deposits 1/2 11Increased IgA1 plasma levels
Increased lambda/kappa ratio 1 2Increased polymeric IgA plasma levels
Fibrin deposits 1/2 11Circulating IgA-containing complexes
Circulatory IgA abnormalitiesIncreased IgA synthesis by B lymphocytes
IgA-containing complexes size 7S-19S .19SOther immunological abnormalities
Other blood immunologic abnormalitiesReduced function of the reticuloendothelial system
High IgE plasma levels 1 11Low grade complement activation
High eosinophil cationic protein (ECP)High IgE plasma levels
plasma levels 2 1High incidence of C4B null phenotype
Increased TNF-a and IL-1 urinary excretion
Abnormalities of mucosal barriers
Increased intestinal permeability to 51Cr EDTA
Increased long carbon monoxide diffusion HSPN, since many of the earlier studies did not utilizeCoagulation abnormalities
serial routine urinalysis, and transient microscopic hema-Intact cross-linked fibrin (XFb)
Increased von Willebrand factor plasma levels turia was probably missed [18]. Finally, an underestima-
Abbreviations are: TNF-a, tumor necrosis factor-a; IL-1, interleukin-1. tion could result from the existence of renal lesions with-
out any clinical signs and the delay that can occur between
the initial signs and renal symptoms. Indeed, the incidence
of renal involvement increases with time after HSP diag-
biopsies. This wide range depends on criterion for per- nosis in children [19]. Kaku, Nohara, and Honda have
forming a biopsy, but also on racial features [14]. IgAN shown that the latter percentage increased progressively
seems to be a relative rarity in blacks, in both the United to reach 35.4% after one year and continued to increase
States and Africa. American Indians, on the other hand, thereafter [19]. In contrast to studies in children, the
have a higher incidence of IgAN than the world popula- incidence of renal involvement in HSP in adults has been
tion at large. more precisely assessed in one study using a cohort of
The peak age at the time of the first clinical manifesta- patients in whom the diagnosis was made by showing
tions of primary IgAN ranges between 15 and 30 years the characteristic leukocytoklastic skin vasculitis accom-
[15]. Affected children do not present symptoms before panied by IgA deposits [20]. This study demonstrated
the age of three years; thereafter, they are evenly spread that 49% of patients presented with abnormal urinary
through childhood [16]. Worldwide, the male-to-female signs. In HSPN also, the sex ratio (male:female ratio 1.5)
sex ratio is 2:1 [14]. shows an increased frequency in males [21].
The proportion of HSPN as cause of ESRF in adults
is minimal [17], whereas it can reach up to 5.1% in chil-
CLINICAL FEATURESdren [13]. The prevalence of HSP is difficult to assess
from previously reported studies. Epidemiological stud- The most prominent clinical feature of IgAN is syn-
ies on HSP performed to date have not taken into ac- pharyngitic macroscopic hematuria. Less often, macro-
count the presence of IgA deposits in tissue as a diagnos- scopic hematuria in IgAN is accompanied by other infec-
tic criterium. This is important since the latter is the gold tions (pulmonary, intestinal, or urinary) [22]. In Western
standard of distinguishing HSP from other vasculitides countries, macroscopic hematuria is the most frequent
such as hypersensitivity vasculitis [5]. However, it is gen- initial presentation in children (76 to 100%) [23], fol-
erally agreed that the incidence of HSP decreases with lowed by the fortuitous finding of microscopic hematuria
age [17]. The lack of using appropriate diagnostic criteria accompanied or not by proteinuria (0 to 19%). In con-
possibly explains why the proportion of patients present- trast to children, microscopic hematuria and/or protein-
ing with renal involvement varies considerably among uria are the most frequent initial presentations in adults
the different reports (20 to 100%) according to a review (28 to 61% vs. 12 to 43% for macroscopic hematuria)
from White and Yoshikawa [18]. Another explanation [24]. Renal insufficiency and hypertension are less often
encountered as initial signs, but are more frequent atmight reside in the use of different criteria for diagnosing
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first presentation in adults (15 to 36% and 31 to 43%,
respectively) [24] than in children (4 to 12% and 0 to
18%, respectively) [23]. In a few cases, a nephrotic or a
nephritic syndrome can be the first sign in adults (4 to
13%) [24] but also in children (4 to 8%) [23]. Finally,
in some adult patients, the diagnosis is made when ESRF
is already present [25].
A history of a recent or simultaneous infection is also
common in HSP. Indeed, the latter is reported in one
third to two thirds according to the studies [17]. Although
any of the four major components of the syndrome (rash,
Fig. 1. Relationship between initial clinical signs and risk of chronicjoint pain, abdominal symptoms, and renal disease) may
renal failure in Henoch-Scho¨nlein purpura nephritis (HSPN) [25].
be present before the other, it is rare for the renal disease
to do so [17]. According to a single series from a tertiary
center [25], initial signs of HSPN are hematuria and
proteinuria in 50% of patients, acute nephritic syndrome abnormalities can lead to chronic renal failure after de-
in 8%, nephrotic syndrome in 13%, and an association cades [25]. The general opinion is that HSP has a worse
of nephritic and nephrotic syndrome in 29% of patients prognosis in adults than in children [reviewed in 33].
[25]. As expected, the incidence of mild symptoms is However, in their study of patients with a clinical presen-
higher in unselected series [26, 27]. Unfortunately, none tation that warranted renal biopsy, Coppo et al showed
of the latter studies used cutaneous IgA deposits as a that HSPN had a similar prognosis in children and adults
diagnostic criterion, and therefore, their results must be [32]. Several risk factors for renal involvement have been
considered with caution. reported in children [19]: older age, abdominal symp-
toms, low factor XIII activity, and persisting purpura. In
adults—unlike children—the patients with renal involve-PROGNOSTIC FACTORS
ment do not seem to differ from those without, according
At 10 years after diagnosis, 15% of adult patients with to any clinical parameter such as sex, prevalence of bul-
IgAN reach ESRF, rising to 25 to 34% at 20 years after lous or necrotic lesions of the skin, or gastrointestinal
diagnosis [24, 28]. Studies about the prognosis of IgAN and joint involvement [20].
in children are contradictory. Yoshikawa, Ito, and Naka- Interestingly, remissions of Henoch-Scho¨nlein pur-
mura have shown that 10% of children with IgAN display pura have been reported during pregnancy or sex-hor-
chronic renal failure after 20 years of follow-up [29]. In mone therapy [34]. The latter observation as well as
contrast, Wyatt et al have shown a similar prognosis in the mean sex ratio (male:female 1.5) is in favor of a
children and in adults [30]. In children as well as in adults, pathogenic role of male hormones. As in IgAN, recur-
the intensity of proteinuria and hypertension and the rence can affect the transplanted kidney and lead to graft
severity of histologic findings are related with evolution loss in 11 to 35% of patients five years after transplanta-
to chronic renal failure [14, 22, 23]. Recurrence in the tion [reviewed in 35].
transplanted kidney is observed in about two thirds of
patients and leads to graft failure in 25% of them [31].
SECONDARY FORMS OF IgAN AND OF HSPAccording to a national multicentric Italian study, the
risk of ESRF in adults with HSPN 10 years after diagno- Secondary forms of IgAN have been extensively re-
viewed by Emancipator [14] and Mustonen and Paster-sis is about 15% and therefore does not differ from that
of IgAN [32]. In childhood, the prognosis of HSPN seems nak [36].
A high proportion of patients presenting with diseasesto be worse than that of IgAN. HSPN leads to chronic
renal failure in 20% of children 20 years after the diagno- involving the liver (for example, alcoholic cirrhosis and
biliary ectasy) or secretory mucosae (celiac and Crohn’ssis [18] compared with 10% of children with IgAN after
the same follow-up period [29]. The risk of chronic renal disease, chronic infection or cancer) have mesangial de-
posits of IgA indistinguishable from those with primaryfailure is related to the initial clinical presentation (Fig.
1) [18, 25]. Chronic renal failure will be encountered IgAN. Secondary forms of IgAN can also be observed
in lymphoproliferative disorders (for example, IgA gam-in less than 5% when clinical signs at presentation are
hematuria and/or minimal proteinuria, 15% when pro- mopathies and non-Hodgkin lymphomas). Finally, auto-
immune and hypersensitivity diseases such as dermatitisteinuria is heavy but not nephrotic or in case of acute
nephritic syndrome, 40% in case of nephrotic syndrome, herpetiformis, ankylosing spondylitis, scleritis, and sun-
dry collagen-vascular diseases are also seen in associationand more than 50% when nephritic and nephrotic syn-
dromes are associated. Of interest, even minimal urinary with mesangial IgAN. In the secondary forms, however,
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the association of complement with IgA deposits is much extent of mesangial proliferation and sclerosis (Fig. 4)
less frequent than in IgAN, and thus, pathological and [14]. The classification of pathologic glomerular changes
clinical signs of inflammatory disease are usually absent. in HSPN is based on endocapillary and extracapillary
Most patients with secondary IgAN have been recog- inflammation of the glomerulus (Fig. 5) [14] and bears
nized at autopsy and had never been observed to have a strong similarity to the glomerular lesions observed in
had urinary or renal functional abnormalities. Episodic systemic vasculitis. Glomeruli show crescents in more
macroscopic hematuria and/or renal insufficiency or pro- than 50% of patients [14]. There is an obvious correlation
teinuria are rarely reported but do occur. between neutrophil glomerular infiltration, endocapil-
In contrast to IgAN, HSPN has been described in lary proliferation, and crescent formation [14, 56, 57].
association with hypersensitivity. Indeed, several drugs
Ultrastructural microscopysuch as ciprofloxacin, acetylsalicylic acid, vancomycin,
carbidopa/levodopa, cocaine, angiotensin-converting en- By ultrastructural microscopy, the finding of electron-
zyme inhibitors, carbamazepine, and streptokinase have dense deposits in the mesangium confirms the accumula-
been implicated in HSP induction [37–45]. tion of IgA and C3 and is the rule in IgAN and HSPN
Henoch-Scho¨nlein purpura is much less frequently as- [6, 14]. Capillary wall deposits, especially large subepi-
sociated with other diseases than IgAN. Cancer [46], thelial deposits, are frequently associated with the cres-
blunt trauma [47], monoclonal IgA gammopathy [48], cents and synechiae [57]. Subepithelial and subendothel-
Wiskott-Aldrich syndrome carrier status [49], and chron- ial deposits are more frequently seen in HSPN than in
ic alcoholic liver disease [50] have been reported as pos- IgAN, and their size is directly related with the severity
sible causes of HSPN. of histology [14].
Henoch-Scho¨nlein purpura has been reported in asso-
ciation with a1-antitrypsin deficiency in two patients [51].
OTHER ORGAN INVOLVEMENTA case of rapidly progressive glomerulonephritis associ-
ated with IgG and IgA ANCAs has been described re- Histologically, cutaneous HSP is a leukocytoclastic
cently in a patient with IgAN [52]. form of vasculitis, with vessel wall necrosis and perivascu-
lar accumulation of inflammatory cells, mostly polymor-
phonuclear leukocytes (PMNLs) and mononuclear cells,RENAL PATHOLOGY
surrounding the capillaries and postcapillary venules ofImmunofluorescence
the dermis [57, 58]. Immunofluorescence staining reveals
Per definition, predominant IgA deposits are observed the presence of IgA, C3c, a complex of C41C3c1C3d,
in the mesangium of all glomeruli in IgAN (Fig. 2) [6]. fibrin/fibrinogen, rarely C4, and no C1Q in vessels and
In HSPN, mesangial IgA also is an almost constant find- connective tissue of clinically involved and uninvolved
ing [7]. In the latter disease, however, capillary wall stain- skin [59], which suggests an activation of the complement
ing for IgA is more frequently found and may even system by the alternative pathway.
predominate on mesangial IgA, which might be absent Baart de la Faille-Kuyper et al also have shown IgA
in some rare cases (Fig. 3) [reviewed in 14]. Extensive deposits constantly accompanied by C3c and the com-
capillary deposits are associated with more severe diffuse plex of C41C3c1C3d in the cutaneous capillary walls
endocapillary proliferation and/or extensive crescent for-
of 33 out of 36 patients with IgAN [59]. IgM depositsmation in both diseases [reviewed in 14].
were found in half of the patients and IgG only in a fewGlomerular deposits of IgG and IgM are also found
(5 of 33). Several other groups have confirmed thesein variable proportions in IgAN and HSPN [6, 7, 14,
findings in approximately 50% of patients with IgAN23]. In both diseases, C3 and alternative complement
[14].pathway components are also frequently found, but com-
Also in the digestive tract, a leukocytoclastic vasculitisplement factors of the classic pathway are rarely demon-
accompanying IgA deposits has been reported in HSPstrated [6, 7, 14, 23]. In IgAN, mesangial IgA deposits
[60].are almost exclusively composed of IgA1, with a larger
The clinical association of respiratory tract infectionsproportion of polymeric form and of lambda chains than
with acute episodes of HSP and macroscopic hematuriain normal circulating IgA [53–55]. In HSPN, polymeric
episodes in IgAN suggests a triggering role for infectiousIgA1 mesangial deposits are also found, but the ratio of
agents in the pathogenesis of both diseases. Secretorylambda chains remains normal [reviewed in 14]. Interest-
IgA in the mucosal lining plays a major role in the de-ingly, glomerular fibrin deposits are much more fre-
fense against exogenous antigens. In the circulation, thequently present in HSPN than in IgAN [14].
antigens can be captured by circulating IgA1. Thus,
Light microscopy formed IgA-containing complexes (IgA-CCs) are cleared
by the asialoglycoprotein receptor of hepatocytes, whichAt light microscopy, glomerular lesions of IgAN have
been classified mainly according to the presence and binds the oligosaccharidic chains of the IgA1 Fc frag-
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Fig. 2. Immunofluorescence micrograph of a glomerulus from a patient Fig. 3. Immunofluorescence micrograph of a glomerulus from a patient
with IgA nephropathy (IgAN) stained for the presence of IgA. A with HSP nephropathy stained for the presence of IgA. A granular,
coarsely granular, mesangial staining pattern can be observed (3250). partial capillary, partial mesangial staining pattern can be observed
(3200).
Fig. 5. Light micrograph of a glomerulus from the same patient withFig. 4. Light micrograph of a glomerulus from the same patient with
HSP nephropathy as in Figure 3 with influx of neutrophils, fibrinoidIgAN as in Figure 2 showing mesangial expansion caused by accumula-
necrosis, and intracapillary and extracapillary proliferation, a patterntion of extracellular matrix and hypercellularity. Methenamine silver
typical for systemic vasculitis. Methenamine silver (3200).(3250).
ment. Other clearance mechanisms involve the recogni- IMMUNOLOGICAL ABNORMALITIES
tion of other components of IgA-CC [reviewed in 11]. Plasma IgA
The finding of IgA1 deposits in glomeruli and the rela- Increased IgA plasma concentrations have been found
tionship between their localization pattern and the type in various percentages of patients in IgAN and HSPN
of histologic lesions strongly suggest their pathogenetic [reviewed in 10, 11, 24]. In both diseases, the increase
role as well as a dysfunction of the IgA system. The mainly involves polymeric IgA1. Qualitative abnormali-
latter theoretically might concern the control of IgA1 ties of IgA molecules might favor IgA-CC formation or
synthesis, IgA1 specificity for antigens that should favor their binding to MCs or extracellular matrix. IgAN—but
the formation of IgA-CC, the penetration of antigens not HSPN—is characterized by raised plasma lamda-IgA1,
inside of the organism, IgA-CC clearance, and finally which preferentially binds to mesangial cells [55, 61].
physiochemical and biological properties of IgA and IgA antibody specificities to endogenous (for example,
IgA-CC, which allow their accumulation in the mesan- IgG Fc and Fab fragments, IgA, endothelial cells, albumin,
gium and in perivascular sites and provoke tissue lesions. simple-strand DNA) or exogenous antigens (for example,
The following section explores the data in the litera- pneumococcus polysaccharides, Haemophilus influenzae,
ture on the IgA system in IgAN and HSPN. We also lactalbumin, ovalbumin, gliadin, anti-a galactosyl anti-
focus on the differences between the two diseases and bodies) were reported in IgAN. Some of them, such as
IgA rheumatoid factor and anti-a galactosyl antibodies,propose pathogenetic mechanisms.
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have also been found in HSPN [reviewed in 11, 24]. Early differences concerning IgA-CC were noted between the
two diseases except for the size of complexes and theirreports of plasma anti-neutrophil cytoplasmic antibody
(ANCA) in IgAN and HSPN could not be confirmed, IgG content. Indeed, using sucrose density gradient ul-
tracentrifugation and polyethylene glycol precipitationand have been attributed to technical artifacts and to
aspecific binding based on lectin-like or electrostatic in- of circulating IgA-CC, Levinsky and Barratt [85] and
thereafter Kauffman, van Es, and Daha [86] have re-teractions [32, 62–64].
In both diseases, increased binding of IgA to fibronec- ported that circulating IgA-CCs were concentrated en-
tirely in the 7S-19S peak in IgAN, whereas those fromtin (FN) leads to IgA-FN complex formation [65, 66],
whereas incomplete glycosylation of IgA [24, 67–69] fa- HSPN were also found in a peak greater than 19S. Addi-
tionally, Levinsky and Barratt [85] and Cederholm et alvors the formation of IgA-lectin complexes, IgA1-IgG,
or IgA1-IgA1 aggregates [24, 70–73]. Abnormally glyco- [65] have shown higher amount of IgG in IgA-CC from
patients with HSPN than in those with IgAN. In experi-sylated IgA1 was demonstrated in HSPN, but not in
patients presenting with HSP without renal involvement mental models of IgAN, some features of IgA-CC such
as the type of antigen used and their content in polymeric[74]. The latter observation may explain why not all
patients with HSP present with renal involvement. IgA and in IgG seem crucial for induction of glomerular
lesions [reviewed in 82].
IgA synthesis
Clearance of IgA complexesIncreased synthesis of IgA has been demonstrated in
both diseases [75, 76]. In IgAN, increased IgA produc- The formation of circulating IgA-CC is a normal pro-
cess involved in the clearance of mucosal antigens thattion is at least partly related to a dysregulation of B-cell
control by T lymphocytes, with increased proportions of escape the mucosal barrier protective mechanisms and
enter the organism. IgA-CCs are mainly cleared by theactivated T helper cell subpopulations and decreased
proportions of activated T-suppressor cells [77, 78]. liver after binding of IgA to hepatocyte receptors for
asialoglycoproteins [87, 88]. Thereby, hepatic clearanceMoreover, coculture experiments displayed enhanced T
helper and decreased T suppressive functions [79]. In- of IgA-CC prevents accumulation in the circulation and
deposition in other organs such as the kidney. Highcreased production of T cells cytokines [interleukin (IL)-2,
interferon-g, IL-4, IL-5, and IL-6) can also be involved plasma levels of IgA-CC may theoretically result from
an increase production or a reduced clearance or both.in this stimulation in IgAN [77, 80, 81]. The regulation
of B cells by T lymphocytes in HSPN has not been stud- IgA-containing compounds’ clearance depends also
on the mononuclear phagocyte system function. Apartied so far.
from IgA, IgA-CCs also may contain IgG, IgM, FN, and
IgA complexes complement components [24, 65, 89–91]. Although Fca
receptors on blood cells are down-regulated in IgANGlomerular deposition of circulating IgA-CC is
thought to play a crucial role in the development of [92], liver clearance of aggregates prepared from normal
IgA is normal in IgAN [93]. However, abnormally glyco-mesangial proliferation and extracellular matrix produc-
tion leading to glomerular sclerosis in IgAN and HSPN. sylated IgAs found in IgAN and in HSPN [24, 68, 74,
79] are possibly less efficiently cleared by the hepatocyteThis hypothesis results partly from the analysis of glo-
meruli and serum of patients. Besides, the pathogenic receptor for asialoglycoproteins than normal IgA. In
contrast to normal IgA clearance mechanisms, a reduc-role of IgA-CC is also suggested in various experimental
models of IgAN resulting from glomerular deposition of tion of Fcg, C3b, and FN receptor function of mono-
nuclear phagocytes was reported in IgAN and HSPNcirculating IgA-CC either preformed and injected intra-
venously or endogenously synthesized [82]. Glomerular [94, 95]. These abnormalities were mostly not correlated
with clinical signs and transient, and therefore are moreIgA is at least partly polymeric (pIgA) and belongs to
the IgA1 isotype in both diseases [14, 53, 83]. The dissoci- probably secondary to saturation of receptors rather
than a primary event.ation of high molecular weight IgA eluted from glomeruli
by acidic pH also strongly suggests the presence IgA-
Antigen penetrationCCs in glomeruli [54]. High levels of circulating IgA-CC
have been demonstrated by various methods in IgAN Increased formation of circulating IgA-CC in IgAN
can be the consequence of transmucosal penetration of[reviewed in 24] and HSPN [reviewed in 10]. These com-
plexes contain IgA1 and also IgA2, IgG, and FN. The exogenous antigens. The intestinal permeability to 51Cr
EDTA is increased in IgAN and HSPN [96, 97]. Thiscorrelation between their detection and the presence and
intensity of hematuria in IgAN was reported in several increase is correlated with circulating IgA-CC plasma
levels and with hematuria as well as with systemic symp-studies [reviewed in 24]. Likewise, IgA-CCs are gener-
ally found during acute phases of HSPN and are also toms in HSPN [96, 97]. Transiently increased lung trans-
fer for carbon monoxide (TCLO) has been reported incorrelated with hematuric episodes [65, 76, 84]. No major
Davin et al: IgAN and HSPN 829
acute phases of IgAN and HSPN [98, 99]. The reason Immunogenetic factors
for this increased mucosal permeability remains un- Several lines of evidence have revealed that immuno-
known. Its reversibility suggests that it is most probably genetic factors are involved in the pathogenesis of IgAN.
secondary to alterations of the mucosal capillaries caused First, a number of familial cases have been reported
by deposition of IgA containing immune complexes. In- [119]. Furthermore, IgAN is rare in black people [14].
creased penetration of antigens inside of the human or- An increased production of IgA by lymphocytes in vitro
ganism may also result from a lack of specific mucosal has been described in healthy relatives of patients [120].
IgA production, as demonstrated recently by de Fijter The unusual polymorphism of the heavy chain switch
et al using intranasal immunization with cholera toxin region and the abnormally high frequency of homozy-
subunit B as a novel antigen in patients with IgAN [100]. gote phenotypes C4B nul, C3FF and BfFF are also in
Many studies have implicated viral agents such as cyto- favor of the intervention of immunogenetic factors in
megalovirus, Epstein-Barr, and hepatitis B virus as etio- IgAN [121, 122]. Immunogenetic studies in HSPN have
logic factors in IgAN [101–104]. Hemophilus para- also demonstrated a strong link with homozygous C4A
influenzae antigens are found in the glomeruli of all or C4B null phenotype [123].
patients with IgAN but not in those with other glomeru-
lar diseases [105]. Alimentary antigens such as soy, rice,
COAGULATION
and cow milk proteins have been detected in a variable
The coagulation system is possibly involved in thepercentage of cases, reaching 75% for soy [106, 107].
pathogenesis of IgAN and HSPN, as suggested by quanti-These data indicate that several different antigens are
tative and functional deficit of plasminogen in IgANprobably involved in the pathogenesis of IgAN. Some
[124], the presence of a circulating factor able to inhibitauthors suggest that undergalactosylated IgA1 itself may
PGI2 synthesis in IgAN and HSPN [125], the depletionplay the role of antigen [74].
of fibrin-stabilizing factor (factor XIII) in acute HSP,
the increased von Willebrand factor plasma levels foundAllergy
in HSPN and IgAN [126–128], and the intact cross-linkedSeveral studies have documented the association of
fibrin (XFb) intraglomerular deposits in IgAN andHSP with hypersensitivity type 1 [37–45]. Early studies
HSPN [129]. As already mentioned, glomerular fibrinreported high IgE plasma levels in HSP [95, 108]. Studies
deposits are more abundant in HSPN than in IgAN.of IgE plasma levels in IgAN are conflicting [109–112].
Although most of those coagulation abnormalities areHigh IgE plasma levels have been preferentially found
probably secondary to a previous damage of the endo-in patients with mild histologic changes and proteinuria
thelium, they may contribute to further deterioration ofresponding to steroids [112]. Davin et al have found that
glomerular structures and particularly to the formationthe incidence of increased plasma IgE levels according
of glomerular crescents.to age-matched normal values were significantly higher
in HSPN than in IgAN [109]. Moreover, IgE deposits
were demonstrated on cutaneous Langerhans and mast PATHOGENESIS OF GLOMERULAR LESIONS
cells in four out of six patients with HSPN. Recently, The deposition of IgA-CC in glomeruli is favored by
Namgoong, Lim, and Kim have shown that serum eosin- their high plasma concentration in IgAN and HSPN.
ophil cationic protein (ECP) levels were elevated in HSP, Their preferential accumulation in the mesangial area is
but not in IgAN, as compared with normal controls [113]. at least partly related to their relative large size [54, 130,
Furthermore, these levels were higher in HSP with than 131]. Once in the mesangium, different components of
in HSP without renal involvement. IgA-CC (for example, Fca and Fcg fragments, FN, C3b,
lectins) can bind to their specific receptors on the surface
Complement of mesangial cells (MCs) [reviewed in 132]. Moreover,
The plasma concentrations of the different compo- the physicochemical properties of plasma IgA in IgAN
nents of the complement system are generally normal and HSPN favor their binding to MCs and their stimula-
in IgAN and HSPN [95, 114]. However, an activation of tion. Indeed, the binding capacity to MCs of polymeric
the complement cascade does occur since degradation IgA and lambda IgA1 is higher than monomeric IgA
products in plasma and glomeruli have been shown in and k IgA1, respectively [61, 133]. Besides, aggregated
both diseases [95, 115, 116]. The role of this activation forms of IgA1, but not monomeric IgA1, are able to
remains unclear. Results of studies trying to correlate stimulate MCs after binding to a receptor different from
the level of complement-split products in the blood with FcaR1 [134]. Interactions of IgA with MC in vitro in-
clinical signs [95, 117, 118] or the glomerular deposition duces the expression and synthesis of chemokines mono-
of various complement factors and histologic lesions are cyte chemoattractant protein-1 (MCP-1) and IL-8 [135,
136], which are overexpressed in glomeruli in IgAN [137]contradictory [95, 115, 116].
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Table 3. Mesangial cell receptors and products tion. Whether massive mesangial immune deposits may
also induce crescent formation by disruption of the over-Receptors Products
lying glomerular basement membrane and subsequentAngiotensin II IL-1
Adenosine IL-6 podocyte injury is unclear.
Endothelin TNF-a
Prostaglandin PDGF
Putative IgA receptor TGF-b PATHOGENESIS OF
Fcg R ECM components
LEUKOCYTOCLASTIC VASCULITISC3b Metalloproteinases
Lectins Invasion of leukocytes involves a three-step process
ECM components
of rolling, sticking, and firm adhesion to endothelial cellsIL-1
IL-6 followed by leukocyte migration into the tissues. This
IL-8 process is regulated by a network of cytokines and che-
TNF-a
mokines leading to expression of adhesion molecules onPDGF
TGF-b endothelial and inflammatory cells. The primary event
is probably damage of endothelial cells, which can beAbbreviations are: ECM, extracellular matrix; IL, interleukin; TNF-a, tumor
necrosis factor-a; TGF-b, transforming growth factor-b; PDGF, platelet-derived induced by subendothelial immune-complex deposition
growth factor.
(for example, in serum sickness), binding of cytotoxic
antibodies (for example, in Kawasaki disease), or inter-
action with activated circulating cells (possibly in Wegen-
er’s disease) [reviewed in 144]. The involvement of theseand can account for the attraction of PMNLs and mono-
in HSPN is suggested by the presence of IgA-CC incytes found in patients biopsies. MCs may also be stimu-
plasma and tissues. Why this leads to a systemic vasculitislated by cytokines of the acute phase [IL-1, tumor necro-
in HSPN and not in IgAN remains unknown.sis factor-a (TNF-a), IL-6] and of the chronic phase
A possible role of a more potent activation of PMNL[platelet-derived growth factor (PDGF), transforming
by IgA-CC and/or circulating chemokines in HSPNgrowth factor-b (TGF-b)] produced by themselves (Ta-
should be considered in this respect. The intensity of theble 3) [reviewed in 132] and/or by infiltrating cells. The
cellular response to the binding of extracellular factorsdetection of those cytokines in glomeruli of patients with
depends on the specificity of the receptor-ligand pair,IgAN suggests their role in MC proliferation and extra-
on the amount of ligand bound, and on the simultaneouscellular matrix overproduction [138–141].
binding of other types of ligands. A great number of
neutrophils surface receptors have been described so far
PATHOGENESIS OF EPITHELIAL CRESCENTS [reviewed in 144]. Among these, FcaR, FcgR, CR1, CR2,
As already mentioned, capillary necrosis and glomeru- and CR3 are able to bind to components of IgA-CC
lar crescents are much more numerous in HSPN than in such as IgA and IgG Fc fragments and C3bi [10, 24, 65,
IgAN, and their number is closely related to the severity 85, 86, 89]. It can therefore be postulated that a greater
of clinical signs and to the prognosis in both entities. diversity and a higher amount of ligand present in IgA-
Their presence is related to capillary wall destruction CC in HSPN might result in a higher degree of leukocyte
and is generally associated with endothelial proliferation stimulation. The finding of large-sized IgA-CC with a
as well as with subendothelial deposits [14], as further higher IgG content in HSPN pleads for this hypothesis
discussed later in this article. The role of fibrin deposition [65, 85].
in crescent formation is suggested by the almost constant Chemokines such as IL-8 could also be involved in
presence of glomerular fibrin in HSPN in contrast to the neutrophil recruitment in HSPN. Indeed, IL-8 is a
IgAN [14], and is supported by the experimental work potent neutrophil attractant secreted by circulating cells
of Vassalli and McCluskey [142]. They reported that such as monocytes, eosinophils, and neutrophils as well
the anticoagulant warfarin entirely prevented crescent as by resident cells such as endothelial cells and mast
formation in nephrotoxic serum nephritis in rabbits. Fi- cells. The monocyte cytokine response is stimulated after
brin is a chemoattractant for macrophages that should binding with IgA and IgG in vitro [145, 146]. In HSPN,
play a major role in crescent formation [143]. stimulation of eosinophils is suggested by an increased
All together, those observations suggest that the fol- eosinophil cationic protein (ECP) plasma concentration
lowing succession of events are involved in the crescent [113]. High plasma levels of von Willebrand factor during
formation in HSPN and IgAN: subendothelial deposition the acute phase of HSPN imply stimulation of endothe-
of IgA-CC, stimulation of endothelial cells to express von lial cells [128]. The latter is also suggested by the glomer-
Willebrand factor, initiation of the coagulation cascade ular endothelial proliferation observed in HSPN [14].
leading to glomerular fibrin deposition, macrophages at- Mast cells are also a potential source of IL-8 in HSPN.
Their close apposition to the vasculature places them intraction, and cytokine-induced epithelial cells prolifera-
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